AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-11 and is reviewed periodically as new material appears.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
=== Environmental policy === Tetra Pak products have been identified as a solid waste problem by many NGOs and environmental groups. Unlike aluminum cans or glass bottles, it cannot be recycled in municipal recycling facilities. In order to stave off regulation, the company has engineered a strong Corporate Social Responsibility campaign. In 2011, Tetra Pak published a set of sustainability targets, which included maintaining its CO2 emission levels at the same level until 2020 and increasing recycling by 100 percent. Previous Tetra Pak sustainability targets (2005–2010) were met and exceeded. Maintaining current CO2 emission levels until 2020 would result in a 40 percent relative cut in emissions at an average growth rate of five percent per year, according to Food Production Daily. Tetra Pak said it will increase its use of Forest Stewardship Council (FSC) certified paper to 100 percent in 2020, with an interim target of 50 percent by 2012. The new targets will encompass the whole value chain, from suppliers to customers, putting pressure on partners to perform coherently. As of 2017, Tetra Pak was a Carbon Disclosure Project "A-lister" and 100% of its paperboard that year was either FSC-certified or came from other controlled sources that exclude "five environmentally and socially unacceptable categories as defined by the FSC." The company began producing paper straws for some of its smaller containers in 2019.
==== Operation Enduring Freedom – Trans Sahara ==== In June 2005, the United States replaced the PSI with the launch of the Trans-Saharan Counterterrorism Initiative (TSCTI/TSCTP) for Burkina Faso, Mali, Niger, Chad, Mauritania, Morocco, Algeria, Tunisia, Senegal and Nigeria, with the support from the Department of Defense's Operation Enduring Freedom – Trans Sahara (OEF-TS). The principle SOF unit for the TSCTP/TSCTI was the 10th SFG, which was joined by the 20th SFG, as the 3rd SFG (who had regional responsibility for Africa) was assigned to Iraq. This meant the Green Berets in the region lacked the cultural and language prerequisites that the 3rd SFG had, and so the Green Berets were forced into a mission that they, like the targeted countries were "learning on the job". In 2005 and 2007, US Army Special Forces and US Army Rangers, along with contingents from other units participated in the JCET's Flintlock Exercises, where they provided training experience both for American troops and for troops of African countries. Small numbers of European troops were also involved in these exercises. The first test of the TSCTI, which "kicked off" the Saharan counterterrorism initiative was Flintlock 2005, lasted from 6–26 June 2005, and was designated by the Bush administration as the largest American military exercise in Africa since World War II. 700 special forces participants, supported by an additional 2,100 troops from 9 North and West African states.
=== Chemical characteristics === Hydrogel dressings exhibit chemical or physical cross-linking. Chemical cross-linking involves formation of covalent bonds between polymer chains. Chemically cross-linked hydrogel dressings are synthesized by chain-growth polymerization, step-growth polymerization, enzymes, or irradiation polymerization. Synthetic dressings incorporating nanoparticles such as PVA and polyethylene glycol (PEG) are assembled using chemical cross-linking mechanisms. Physically cross-linked hydrogel dressings are assembled via ionic interaction, hydrogen bonding, hydrophobic interactions, or crystallization. Physically cross-linked hydrogels disintegrate due to local changes in pH, ionic strength, and temperature. Natural dressings incorporating polysaccharides and proteoglycans/proteins form a 3D network using physical cross-linking. Hydrogel dressings mimic the cross-linked 3D network of extracellular matrix fibers in human skin. Hydrogels can be formed through a self-assembly process in which monomers diffuse in solution then form noncovalent interactions. Hydrogels used in wound dressings can be self-assembled upon addition of divalent metal cations or electrically charged polysaccharides due to electrostatic interactions. Self-assembly via hydrophobic interactions can be induced in amphiphilic polysaccharide-based gels by addition of water; it can also be induced in non amphiphilic polysaccharide-based hydrogels by the addition of hydrophobic grafts.
== Locations == Most Pyongyang restaurants are found near the North Korean border in China, as well as in Beijing and Shanghai. Since the 2000s, the chain has been expanding into South and Southeast Asian cities including Phnom Penh, Siem Reap, Ho Chi Minh City, Hanoi, Da Nang, Vientiane, Dhaka, Jakarta, and Kuala Lumpur. There are also restaurants in Ulaanbaatar, Vladivostok, Moscow, and Kathmandu. The restaurants initially catered to the many South Korean businessmen in Southeast Asia, and have now become popular with curious tourists. The first Western outpost of the restaurant chain was opened in Amsterdam in 2012, in the residential neighbourhood of Osdorp, along with Dutch co-owners. The menu and policies of this restaurant differed from its Asian counterparts. However, in September 2012, amid mutual accusations between the Korean staff and the Dutch partner, the restaurant closed. It reopened in December 2013 under the name Haedanghwa in a new location, but closed a year later. The restaurant's locations in Bangkok were temporarily shut down, but were re-opened again in 2015. Similarly, their branches in Pattaya were closed down. The branch in Ho Chi Minh City closed down in 2017 and the branch in Hanoi shut down in 2020. It was reported that a new branch was set to open in Scotland, in line with North Korean leader Kim Jong Un's interest in the country after its 2014 independence referendum, although this has been denied by North Korean officials. In 2017, there are some 100 North Korean restaurants in China alone.
While classical Jewish law neither requires nor prohibits the consumption of meat, Jewish vegetarians often cite Jewish principles regarding animal welfare, environmental ethics, moral character, and health as reasons for adopting a vegetarian or vegan diet. Rabbis may advocate vegetarianism or veganism primarily because of concerns about animal welfare, especially in light of the traditional prohibition on causing unnecessary "pain to living creatures" (tza'ar ba'alei hayyim). Some Jewish vegetarian groups and activists believe that the halakhic permission to eat meat is a temporary leniency for those who are not ready yet to accept the vegetarian diet. The book of Daniel starts in its first chapter with the benefits of vegetarianism. Due to its size, its late time of origin and its revealing content, the book is of particular importance for the time of the following exile, which lasts now for 2000 years and technically still goes on until the Temple in Jerusalem is rebuilt. A diet described as "pulse and water" is presented along benefits such as accordance with the biblical dietary laws, health, beauty, wisdom and vision. Vegetarianism can be seen as a safeguard around the dietary laws or the beautification of them. Jewish vegetarianism and veganism have become especially popular among Israeli Jews. In 2016, Israel was described as "the most vegan country on Earth", as five percent of its population eschewed all animal products. Interest in veganism has grown among both non-Orthodox and Orthodox Jews in Israel.
Sources: en.wikipedia.org
Vitamin B12 is included in multivitamin pills; in some countries grain-based foods, such as bread and pasta, are fortified with B12. In the US, non-prescription products can be purchased providing up to 1,000 μg each, and it is a common ingredient in energy drinks and energy shots, usually at many times the recommended dietary allowance of B12. The vitamin can also be supplied on prescription and delivered via injection or other means. When used in supplementation, all of the vitamin B12 vitamers have been argued to be beneficial, with there not being clear evidence that any are relatively more or less effective. The amount of cyanide in cyanocobalamin is generally not considered a health risk, since even in a 1,000 μg dose, the 20 μg of cyanide it contains is less than the daily consumption of cyanide from food.
== Comparison to alternatives == Kidney transplantation offers superior survival (~80% at 5 years) and is recommended when eligible. For frail elderly patients, conservative management without dialysis may yield similar survival but better quality of life.
The 1955 census enumerated the colony's 103,879 Arabs as Aden Arabs (36,910), Protectorate Arabs (18,881) and Yemeni Arabs (48,088). The European population consisted of 3,763 British (including military) and 721 other Europeans. The colony's Somali population predated the arrival of the British in Aden. The colony's Jewish population (qv.) had been over 7,000 in 1946, but dropped following the removal of most Jews to the new state of Israel in Operation Magic Carpet. The colony's estimated population grew to well over 200,000 in the 1960s.
== Histology == The epididymis is covered by a two-layered pseudostratified epithelium. The epithelium is separated by a basement membrane from the connective tissue wall, which has smooth muscle cells. The major cell types in the epithelium are:
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.